Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome

  title={Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome},
  author={Sean J. Pittock and Thomas J. Kryzer and Vanda A. Lennon},
  journal={Annals of Neurology},
We investigated coexisting autoantibodies in sera of 553 patients with a neurological presentation and one or more paraneoplastic neuronal nuclear or cytoplasmic autoantibodies: antineuronal nuclear autoantibody type 1 (ANNA‐1), ANNA‐2, ANNA‐3; Purkinje cell cytoplasmic autoantibody type 1 (PCA‐1), PCA‐2; and CRMP‐5–immunoglobulin G or amphiphysin–immunoglobulin G. Except for PCA‐1, which occurred alone, 31% of sera had more than one of these autoantibodies. In addition, 25% of sera had… 

Presence of paraneoplastic antibodies in non-carcinomatous patients with neurological involvements of unknown cause

Paraneoplastic encephalomyelopathies: pathology and mechanisms

The neuropathological findings and pathophysiology of paraneoplastic CNS disorders with reference to antigen-specific serology and neurological and oncological contexts are described.

Multifocal neuropathy as the presenting symptom of Purkinje cell cytoplasmic autoantibody‐1

Multifocal neuropathy with face pain and treatment‐resistance is a specific clinical pattern associated with PCA‐1‐IgG autoantibodies and ovarian cancer.

CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG

For a 25-year period of testing by standardized indirect immunofluorescence protocols, the frequency of neural autoantibody detection in serum and CSF is reported to be the same.

SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes

SOX1 reactivity is described for the first time overlapping with CV2/CRMP5 and amphiphysin antibodies and is predominantly associated with Hu antibodies and SCLC, but can occur also in other types of lung cancer.

Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG

The neuropathy phenotypes in patients affected by MAP1B-IgG autoimmunity are described and recognition of this paraneoplastic neuropathy phenotype may aid early detection of underlying malignancy.

Amphiphysin autoimmunity: Paraneoplastic accompaniments

Only 10% of women (some with lung carcinoma) and 4% of men fulfilled diagnostic criteria for stiff‐man syndrome, and patients with isolated amphiphysin‐IgG were more likely to be women and to have myelopathy or stiff‐ man phenomena.

Paraneoplastic and idiopathic autoimmune neurologic disorders: approach to diagnosis and treatment.